OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer
State on share capital and voting rights (FR)
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.